Autori: Ede NJ
| Naslov | HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome (Meeting Abstract) |
| Autori | Tobias Joshua Kundi Michael Garner-Spitzer E Zielinski Christoph Maglakelidze Marina Andric Zoran G Petrovic Z Nagarkar R Chawla T Chong LO Nixon B Yavrom S Ede NJ Wiedermann Ursula |
| Info | ANNALS OF ONCOLOGY, (2023), vol. 34 br. , Suppl. 2, str. S864-S864 |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome (Meeting Abstract) |
| Autori | Tobias Joshua Kundi Michael Garner-Spitzer E Zielinski Christoph Maglakelidze Marina Andric Zoran G Petrovic Zeljko M Nagarkar R Chawla T Chong LMO Nixon B Yavrom S Ede NJ Wiedermann Ursula |
| Info | ANNALS OF ONCOLOGY, (2023), vol. 34 br. , Suppl. 1, str. S4-S4 |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
| Naslov | HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer (Meeting Abstract) |
| Autori | Maglakelidze Marina Ryspayeva D Andric Zoran G Petrovic Zeljko M Bulat IV Nikolic Ivan V Chawla T Nagarkar R Wiedermann Ursula Blumenstein BA Chong LMO Ede NJ Nixon B Good AJ |
| Info | ANNALS OF ONCOLOGY, (2022), vol. 38 br. 9, Suppl. 9, str. S1460-S1460 |
| Projekat | Imugene Limited |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa |
